Amgen Inc (AMGN) Q1 2026 Earnings Call Transcript

Why It Matters

The raised guidance signals Amgen’s ability to offset upcoming patent expirations with fast‑growing biologics, reinforcing its competitive position in cardiovascular, bone health and rare‑disease markets.

Key Takeaways

• Sales grew 4% YoY, driven by six growth drivers.
• Repatha up 34%, Evenity up 27%, TEPEZZA up 29%.
• Rare disease portfolio +25% YoY, Eplizna +188%.
• Non‑GAAP margin steady at 45%, free cash flow $1.5B.
• Guidance raised: revenue $37.1‑38.5B, EPS $21.7‑23.1.

Pulse Analysis

Amgen’s Q1 performance underscores a strategic shift from reliance on legacy blockbusters toward a diversified portfolio of high‑growth biologics. The company’s six key drivers—spanning cardiovascular, bone health, inflammatory, rare‑disease and oncology segments—delivered a combined 24% sales acceleration, cushioning the impact of biosimilar competition on older assets. This breadth of growth not only stabilizes near‑term earnings but also positions Amgen to capture emerging market opportunities, such as expanded PCSK9‑inhibitor use after the VESALIUS‑CV trial and broader adoption of subcutaneous delivery platforms.

Pipeline momentum further amplifies Amgen’s outlook. Late‑stage programs like Meritide, a long‑acting GLP‑1 therapy, and Olpasiran, an Lp(a)‑lowering agent, promise to open new revenue streams in obesity, diabetes and cardiovascular risk reduction. The company’s AI‑driven R&D initiatives have already accelerated antibody lead optimization by 50%, suggesting faster time‑to‑market for future innovations. Coupled with a robust biosimilar franchise that generated $835 million this quarter, Amgen is building a resilient growth engine that can sustain profitability even as flagship patents expire.

Financially, Amgen’s disciplined cost structure—maintaining a 45% non‑GAAP operating margin—and strong free‑cash‑flow generation enable continued shareholder returns, highlighted by a 6% dividend hike. The raised 2026 guidance reflects confidence in sustaining double‑digit growth across its core brands while navigating tax‑related uncertainties and cost‑of‑sales pressures. Investors should watch how Amgen leverages its manufacturing expansion and AI capabilities to scale upcoming launches, as these factors will be critical in delivering the projected revenue and earnings upside.